Asociación entre la exposición prolongada a inhibidores de la bomba de protones y la prescripción de medicamentos para el abordaje de la osteoporosis en pacientes adultos asegurados al sistema de salud colombiano

dc.contributorHernández Herrera, Gilma Norela
dc.creatorPortilla Pinzón, Alfredo
dc.creatorMuñoz Claros, Conny Stefanny
dc.creatorCastro Becerra, Ricardo
dc.creatorGuatava Redondo, Lina Fernanda
dc.date.accessioned2021-02-19T20:54:24Z
dc.date.accessioned2022-09-22T14:36:27Z
dc.date.available2021-02-19T20:54:24Z
dc.date.available2022-09-22T14:36:27Z
dc.date.created2021-02-19T20:54:24Z
dc.identifierhttps://repository.urosario.edu.co/handle/10336/30951
dc.identifierhttps://doi.org/10.48713/10336_30951
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/3440451
dc.description.abstractBackground: In the past years the proton pump inhibitors have raised a paramount interest in the medical literature due to its adverse events; however, available observational studies do not allow to conclude if they are associated with the prescription of drugs to treat osteoporosis. Study Objective: To determine the association between proton pump inhibitors' long-term exposure and the prescription of osteoporosis drug treatment, adjusting by sociodemographic, clinical and pharmacological variables, in adult patients in Colombia between 2013 and 2018. Methods: A quantitative cohort observational study with retrospective recollection of the information. Conditional logistic regression and survival analysis were applied to estimate the association and to determine the time to the event, respectively. Results: The long-term exposure (OR 1.103 CI95% 0.483-2.52) and the exposure to other drugs with potential outcome as osteoporosis (OR 3.724 CI% 0.852-16.28) were not statistically significant (p>0.05); therefore, the final logistic model was adjusted by age (OR 1.06 CI95% 1.03-1.084), comorbidities (OR 3.34 CI95% 1.27-8.81) and sex (OR 12.82 CI95% 3.05-53.94) (p<0.05), in which the risk was greater in women and directly related to the age. The median time to be prescribed with any drug to treat osteoporosis due to proton pump inhibitors' long-term exposure was approximately 22 months (CI95% 0.345-0.683). Conclusions: It was found that the long-term exposure is not associated with the prescription of osteoporosis drug treatment; nonetheless, further studies are needed to ensure the outcome. A responsible formulation of drugs by the medical team is critical, considering risk and benefit for each patient.
dc.languagespa
dc.publisherUniversidad del Rosario
dc.publisherMaestría en Epidemiología
dc.publisherEscuela de Medicina y Ciencias de la Salud
dc.rightshttp://creativecommons.org/licenses/by-nc-nd/2.5/co/
dc.rightsinfo:eu-repo/semantics/openAccess
dc.rightsAbierto (Texto Completo)
dc.rightsEL AUTOR, manifiesta que la obra objeto de la presente autorización es original y la realizó sin violar o usurpar derechos de autor de terceros, por lo tanto la obra es de exclusiva autoría y tiene la titularidad sobre la misma. PARGRAFO: En caso de presentarse cualquier reclamación o acción por parte de un tercero en cuanto a los derechos de autor sobre la obra en cuestión, EL AUTOR, asumirá toda la responsabilidad, y saldrá en defensa de los derechos aquí autorizados; para todos los efectos la universidad actúa como un tercero de buena fe. EL AUTOR, autoriza a LA UNIVERSIDAD DEL ROSARIO, para que en los términos establecidos en la Ley 23 de 1982, Ley 44 de 1993, Decisión andina 351 de 1993, Decreto 460 de 1995 y demás normas generales sobre la materia, utilice y use la obra objeto de la presente autorización. -------------------------------------- POLITICA DE TRATAMIENTO DE DATOS PERSONALES. Declaro que autorizo previa y de forma informada el tratamiento de mis datos personales por parte de LA UNIVERSIDAD DEL ROSARIO para fines académicos y en aplicación de convenios con terceros o servicios conexos con actividades propias de la academia, con estricto cumplimiento de los principios de ley. Para el correcto ejercicio de mi derecho de habeas data cuento con la cuenta de correo habeasdata@urosario.edu.co, donde previa identificación podré solicitar la consulta, corrección y supresión de mis datos.
dc.rightsAtribución-NoComercial-SinDerivadas 2.5 Colombia
dc.sourceTargownik LE, Goertzen AL, Luo Y, Leslie WD. Long-Term Proton Pump Inhibitor Use Is Not Associated with Changes in Bone Strength and Structure. Am J Gastroenterol [Internet]. 2017;112(1):95–101. Available from: http://dx.doi.org/10.1038/ajg.2016.481
dc.sourceTargownik LE, Lix LM, Metge CJ, Prior HJ, Leung S, Leslie WD. Use of proton pump inhibitors and risk of osteoporosis-related fractures. Cmaj. 2008;179(4):319–26.
dc.sourceCorley DA, Kubo A, Zhao W QC. Proton pump inhibitors and histamine-2 receptor antagonists are associated with hip fractures among at-risk patients. Gastroenterology. 2010;138(1):93–101.
dc.sourceArj A, Razavi Zade M, Yavari M, Akbari H, Zamani B A. Proton pump inhibitors use and change in bone mineral density. Int J Rheum Dis. 2016;19(9):864–8.
dc.sourceKumar S, Drake MT, Schleck CD, Johnson ML, Alexander JA, Katzka DA IP. Incidence and predictors of osteoporotic fractures in patients with Barrett’s oesophagus: a population-based nested case-control study. Aliment Pharmacol Ther. 2017;46(11–12):1094–102.
dc.sourceGhosh G, Schnoll-Sussman F, Mathews S KP. Reported proton pump inhibitor side effects: what are physician and patient perspectives and behaviour patterns? Aliment Pharmacol Ther. 2020;51(11):121–8.
dc.sourceMedina Orjuela A, Rosero Olarte Ó, Nel P, Plata R, Sánchez Escobar F, Chalem Choueka M, et al. Consenso Colombiano De Osteoporosis. Rev Colomb Reumatol. 2018;25(3):184–210.
dc.sourceKaye JA JH. Proton pump inhibitor use and risk of hip fractures in patients without major risk factors. Pharmacotherapy. 2008;28(8):951–9.
dc.sourceLin SM, Yang SH, Liang CC HH. Proton pump inhibitor use and the risk of osteoporosis and fracture in stroke patients: a population-based cohort study. Osteoporos Int. 2018;29(1):153–62.
dc.sourceJacob L, Hadji P KK. The use of proton pump inhibitors is positively associated with osteoporosis in postmenopausal women in Germany. Climacteric. 2016;19(5):478–81.
dc.sourceSolomon DH, Diem SJ, Ruppert K, Lian YJ, Liu CC, Wohlfart A, Greendale GA FJ. Bone mineral density changes among women initiating proton pump inhibitors or H2 receptor antagonists: a SWAN cohort study. J Bone Min Res. 2015;30(2):232–9.
dc.sourceBahtiri E, Islami H, Hoxha R, Qorraj-Bytyqi H, Rexhepi S, Hoti K, Thaçi K, Thaçi S KÇ. Esomeprazole use is independently associated with significant reduction of BMD: 1-year prospective comparative safety study of four proton pump inhibitors. J Bone Min Metab. 2016;34(5):571–9.
dc.sourceHansen KE, Nieves JW, Nudurupati S, Metz DC PM. Dexlansoprazole and Esomeprazole Do Not Affect Bone Homeostasis in Healthy Postmenopausal Women. Gastroenterology. 2016;156(4):926–34.
dc.sourceMaes ML, Fixen DR LS. Adverse effects of proton-pump inhibitor use in older adults: a review of the evidence. Ther Adv Drug Saf. 2017;8(9):273–97.
dc.sourceGómez MA, olivares R, Cardona H. Tratamiento empírico de la enfermedad ácido-péptica. Rev Colomb Gastroenterol. 2004;19(1):26–36.
dc.sourceNash DB. The use of medicines in the united states: A detailed review. Am Heal Drug Benefits. 2012;5(7):2012.
dc.sourceCheungpasitporn W, Thongprayoon C, Kittanamongkolchai W, Srivali N, Edmonds PJ, Ungprasert P, et al. Proton pump inhibitors linked to hypomagnesemia: A systematic review and meta-analysis of observational studies. Ren Fail. 2015;37(7):1237–41.
dc.sourcePark CH, Kim EH, Roh YH, Kim HY, Lee SK. The association between the use of proton pump inhibitors and the risk of hypomagnesemia: A systematic review and meta-analysis. PLoS One. 2014;9(11).
dc.sourceYang SD, Chen Q, Wei HK, Zhang F, Yang DL, Shen Y, et al. Bone fracture and the interaction between bisphosphonates and proton pump inhibitors: A meta-analysis. Int J Clin Exp Med. 2015;8(4):4899–910.
dc.sourceKwok CS, Yeong JKY, Loke YK. Meta-analysis: Risk of fractures with acid-suppressing medication. Bone [Internet]. 2011;48(4):768–76. Available from: http://dx.doi.org/10.1016/j.bone.2010.12.015
dc.sourceGomm W, Von Holt K, Thomé F, Broich K, Maier W, Fink A, et al. Association of proton pump inhibitors with risk of dementia: A pharmacoepidemiological claims data analysis. JAMA Neurol. 2016;73(4):410–6.
dc.sourceHaenisch B, von Holt K, Wiese B, Prokein J, Lange C, Ernst A, et al. Risk of dementia in elderly patients with the use of proton pump inhibitors. Eur Arch Psychiatry Clin Neurosci. 2015;265(5):419–28.
dc.sourceShah NH, LePendu P, Bauer-Mehren A, Ghebremariam YT, Iyer S V., Marcus J, et al. Proton pump inhibitor usage and the risk of myocardial infarction in the general population. PLoS One. 2015;10(6):1–16.
dc.sourceEl-Charabaty E, Saifan C, Abdallah M, Naboush A, Glass D, Azzi G, et al. Effects of proton pump inhibitors and electrolyte disturbances on arrhythmias. Int J Gen Med. 2013;6:515–8.
dc.sourceKlepser DG, Collier DS, Cochran GL. Proton pump inhibitors and acute kidney injury: A nested case-control study. BMC Nephrol [Internet]. 2013;14(1):1. Available from: BMC Nephrology
dc.sourceDirección PJ, Farmacia G De, Ministerio S, Sanidad D, Social P. Estudio de utilización de antiulcerosos en España ( 2000-2008 ). 2009;2:49–54.
dc.sourceErratum: Guidance for the prevention of bone loss and fractures in postmenopausal women treated with aromatase inhibitors for breast cancer: an ESCEO position paper (Osteoporos Int, (2012) 23, 11, (2567-2576), 10.1007/s00198-011-1870-0). Osteoporos Int. 2012;23(11):2577.
dc.sourceChubineh S, Birk J. Proton pump inhibitors: The good, the bad, and the unwanted. South Med J. 2012;105(11):613–8.
dc.sourceReimer C, Søndergaard B, Hilsted L, Bytzer P. Proton-Pump Inhibitor Therapy Induces Acid-Related Symptoms in Healthy Volunteers After Withdrawal of Therapy. Gastroenterology [Internet]. 2009;137(1):80-87.e1. Available from: http://dx.doi.org/10.1053/j.gastro.2009.03.058
dc.sourceNgamruengphong S, Leontiadis GI, Radhi S, Dentino A, Nugent K. Proton pump inhibitors and risk of fracture: A systematic review and meta-analysis of observational studies. Am J Gastroenterol [Internet]. 2011;106(7):1209–18. Available from: http://dx.doi.org/10.1038/ajg.2011.113
dc.sourceEom CS, Park SM, Myung SK, Yun JM, Ahn JS. Use of acid-suppressive drugs and risk of fracture: A meta-analysis of observational studies. Ann Fam Med. 2011;9(3):257–67.
dc.sourceAli T, Roberts DN, Tierney WM. Long-term Safety Concerns with Proton Pump Inhibitors. Am J Med [Internet]. 2009;122(10):896–903. Available from: http://dx.doi.org/10.1016/j.amjmed.2009.04.014
dc.sourceHowell MD, Novack V, Grgurich P, Soulliard D, Novack L, Pencina M, et al. Iatrogenic gastric acid suppression and the risk of nosocomial Clostridium difficile infection. Arch Intern Med. 2010;170(9):784–90.
dc.sourceHunfeld NGM, Geus WP, Kuipers EJ. Systematic review: Rebound acid hypersecretion after therapy with proton pump inhibitors. Aliment Pharmacol Ther. 2007;25(1):39–46.
dc.sourceHo PM, Maddox TM, Wang L. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA - J Am Med Assoc. 2009;301(9):937–44.
dc.sourceCharlot M, Ahlehoff O, Norgaard ML, Jørgensen CH, Sørensen R. Annals of Internal Medicine Proton-Pump Inhibitors Are Associated With Increased Cardiovascular Risk Independent of Clopidogrel Use. Ann Intern Med. 2010
dc.sourceScott SA, Owusu Obeng A, Hulot JS. Antiplatelet drug interactions with proton pump inhibitors. Expert Opin Drug Metab Toxicol. 2014;10(2):175–89.
dc.sourceMorales-Torres J, Gutiérrez-Ureña S. The burden of osteoporosis in Latin America. Osteoporos Int. 2004;15(8):625–32.
dc.sourceTaylor Jiménez B, Piñera Andux I, Rodríguez González J, Rodríguez Soria N, López García Y. Factores de riesgo de osteoporosis en el adulto mayor. Rev Cuba Reumatol RCuR. 2009;11(13):35–43.
dc.sourceAziziyeh R, Amin M, Habib M, Garcia Perlaza J, Szafranski K, McTavish RK, et al. The burden of osteoporosis in four Latin American countries: Brazil, Mexico, Colombia, and Argentina. J Med Econ [Internet]. 2019;22(7):638–44. Available from: http://dx.doi.org/10.1080/13696998.2019.1590843
dc.sourceCardona-Ospina J, Medina-Morales DA, Rodríguez-Morales A, Machado-Alba J. Efectos adversos a largo plazo de los inhibidores de la bomba de protones. Perspectiva desde la medicina basada en la evidencia. Rev Colomb Gastroenterol. 2017;31(4):403.
dc.sourceJohnson DA, Katz PO, Armstrong D, Cohen H, Delaney BC, Howden CW, et al. The Safety of Appropriate Use of Over-the-Counter Proton Pump Inhibitors: An Evidence-Based Review and Delphi Consensus. Drugs. 2017;77(5):547–61.
dc.sourceSalazar Madrigal K. Osteoporosis: un problema mayor de salud pública. Rev costarric salud pública. 2008;17(32):75–9.
dc.sourceQuintana Duque MA, Otero Regino W, Melgar Burbano C. Inhibidores de bomba de protones y riesgo de osteoporosis. Rev Colomb Gastroenterol. 2009;24(2):169–79.
dc.sourceWertheimer A, Santella T. Problemas en el uso de Dosis Diaria Definida (DDD) como base estadística para fijar precios de medicamentos y reembolsos. Fed Int la Ind del Medicam [Internet]. 2007;(Ddd):3–20. Available from: https://www.ifpma.org/wp-content/uploads/2016/01/IFPMA_DDD_2007_SP.pdf
dc.sourceAbrahamsen B, Eiken P ER. Proton pump inhibitor use and the antifracture efficacy of alendronate. Arch Intern Med. 2011;171(11):998–1004.
dc.sourceAndersen BN, Johansen PB, Abrahamsen B. Proton pump inhibitors and osteoporosis. Curr Opin Rheumatol. 2016;28(4):420–5.
dc.sourceGhebremariam YT, Lependu P, Lee JC, Erlanson DA, Slaviero A, Shah NH, et al. Unexpected effect of proton pump inhibitors: Elevation of the cardiovascular risk factor asymmetric dimethylarginine. Circulation. 2013;128(8):845–53.
dc.sourceBundred NJ, Campbell ID, Davidson N, DeBoer RH, Eidtmann H, Monnier A, et al. Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: ZO-FAST study results. Cancer. 2008;112(5):1001–10.
dc.sourceAgirrezabala JR, Alfonso I, Armendáriz M, Elola M, Jaio N. Inhibidores de la bomba de protones: Recomendaciones de uso. INFAC. Serv Cent Publicaciones del Gob Vasco Dep Salud. 2014;44:2431–40.
dc.sourceFerrer I, Pérez JM, Herrerías JM. Guía de Seguimiento Farmacoterapéutico sobre Úlcera Péptica [Internet]. Maria Josè Faus. 2016. 56 p. Available from: https://www.ugr.es/~cts131/esp/guias/GUIA_ULCERA.pdf
dc.sourcearanauskaite A, Savickiene A. Osteoporosis: diagnosis, prevention and treatment. Vol. 38, Medicina (Kaunas, Lithuania). 2002.
dc.sourceDepartamento Administrativo Nacional de Estadística DANE. PROYECCIONES DE POBLACIÓN 2005-2020. Colombia. Tablas abreviadas de mortalidad nacionales y departamentales 1985-2020. Proyecciones de población 2005-2020 [Internet]. 2007;4–22. Available from: https://www.dane.gov.co/files/investigaciones/poblacion/proyepobla06_20/8Tablasvida1985_2020.pdf%0Ahttp://www.dane.gov.co/files/investigaciones/poblacion/proyepobla06_20/8Tablasvida1985_2020.pdf
dc.sourceHochberg MC. Changes in Bone Density and Turnover Explain the Reductions in Incidence of Nonvertebral Fractures that Occur during Treatment with Antiresorptive Agents. J Clin Endocrinol Metab. 2002;87(4):1586–92.
dc.sourceZhou B, Huang Y, Li H, Sun W, Liu J. Proton-pump inhibitors and risk of fractures: an update meta-analysis. Osteoporos Int. 2016;27(1):339–47.
dc.sourceJi X, Wang Y, Ma Y, Hu Z, Man S, Zhang Y, et al. Improvement of disease management and cost effectiveness in Chinese patients with ankylosing spondylitis using a smart-phone management system: A prospective cohort study. Biomed Res Int. 2019;2019.
dc.sourceJi X, Wang Y, Ma Y, Hu Z, Man S, Zhang Y, et al. Improvement of disease management and cost effectiveness in Chinese patients with ankylosing spondylitis using a smart-phone management system: A prospective cohort study. Biomed Res Int. 2019;2019.
dc.sourceJódar Gimeno E. Osteoporosis secundarias. Med. 2014;11(60):3535–44.
dc.sourceGómez-garcía F. Eficacia del tratamiento farmacológico de la osteoporosis en la prevención de fracturas. 2001;15(2):70–85.
dc.sourceMiller PD, Watts NB, Licata AA, Harris ST, Genant HK, Wasnich RD, et al. Cyclical Etidronate in the Treatment of Postmenopausal Osteoporosis. Am J Med [Internet]. 1997 Dec 1 [cited 2018 Nov 22];103(6):468–76. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0002934397002787
dc.sourceKanis JA, Burlet N, Cooper C, Delmas PD, Reginster JY, Borgstrom F, et al. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int. 2008;19(4):399–428.
dc.sourceNational Institute for Health and Care. Alendronate, etidronate, risedronate, raloxifene and strontium ranelate for the primary prevention of osteoporotic fragility fractures in postmenopausal women (amended) | Guidance and guidelines | NICE. 2011;2008(January 2010). Available from: https://www.nice.org.uk/guidance/ta160
dc.sourceÁlvarez Álvarez R, Mendoza Garcés F, Torre Mollinedo F, Callejo Orcasitas A, Arizaga Maguregui A. Actualización en el tratamiento de la osteoporosis. Manejo desde una unidad del dolor (1.a parte). Rev la Soc Esp del Dolor. 2014;21(6):328–37.
dc.sourceGac E H. Polifarmacia y morbilidad. Rev Med Clin Condes. 2012;23(1):31–5.
dc.sourcePinto J. Consenso Osteoporosis Sociedad Gallega de Reumatología. 2014;75(1):S1–3.
dc.sourceVerdejo-Bravo C, Calleja-Panero JL, Guillén-Llera F, Ribera-Casado JM. Estudio epidemiológico sobre la enfermedad ácido-péptica en pacientes ancianos ambulatorios. Rev Esp Geriatr Gerontol [Internet]. 2006;41(1):21–8. Available from: http://www.sciencedirect.com/science/article/pii/S0211139X06729195
dc.sourcePértegas Diaz S, Pita Fernandez S. Cálculo del tamaño muestral para la determinación de factores pronósticos. Cad Aten Primaria. 2002;9:30–3.
dc.sourceS.Clemente:A.Belén;M.Estrada CB. Guía de práctica Clínica.Empleo de los inhibidores de la bomba de protones en la prevención de gastropatías secundarias a fármacos. 2014;111. Available from: www.guiasalud.es/GPC/GPC_509_IBP_gastropatias_2rias_fcos_completa.pdf
dc.sourceHaimanot S, Hayes P, Schuster B. PPI Deprescribing. RxFiles [Internet]. 2017;2015(April 2015). Available from: http://www.rxfiles.ca/rxfiles/uploads/documents/PPI-Deprescribing-Newsletter.pdf
dc.sourceReimer C. Safety of long-term PPI therapy. Best Pract Res Clin Gastroenterol [Internet]. 2013;27(3):443–54. Available from: http://dx.doi.org/10.1016/j.bpg.2013.06.001
dc.sourceSheen E, Triadafilopoulos G. Adverse effects of long-term proton pump inhibitor therapy. Dig Dis Sci. 2011;56(4):931–50.
dc.sourceBustamante Robles KY, Ticse Aguirre R, Cánepa Rondo IF, Costta Herrera CG, Vasquez Kunze S, Soto Arquiñigo L, et al. Frecuencia de la prescripción de los inhibidores de bomba de protones basada en guías de práctica clínica en pacientes hospitalizados en dos hospitales docentes de Lima - Perú. Rev Gastroenterol del Perú. 2012;32(1):44–9.
dc.sourceGreenland S, Mickey RM. Re: “The impact of confounder selection criteria on effect estimation.” Am J Epidemiol. 1989;130(5):1066.
dc.sourcePedrosa I, Juarros-Basterretxea J, Robles-Fernández A, Basteiro J, García-Cueto E. Pruebas de bondad de ajuste en distribuciones simétricas, ¿qué estadístico utilizar? Univ Psychol. 2014;14(1):245–54.
dc.sourceJo Y, Park E, Ahn SB, Jo YK, Son B, Kim SH, Park YS KH. A Proton Pump Inhibitor’s Effect on Bone Metabolism Mediated by Osteoclast Action in Old Age: A Prospective Randomized Study. Gut Liver. 2015;9(5):607–14.
dc.sourceAdams AL, Black MH, Zhang JL, Shi JM JS. Proton-pump inhibitor use and hip fractures in men: a population-based case-control study. Ann Epidemiol. 2014;24(4):286–90.
dc.sourceChen CH, Lin CL KC. Gastroesophageal reflux disease with proton pump inhibitor use is associated with an increased risk of osteoporosis: a nationwide population-based analysis. Osteoporos Int. 2016;27(6):2117–26.
dc.sourceTargownik LE, Lix LM, Leung S LW. Proton-pump inhibitor use is not associated with osteoporosis or accelerated bone mineral density loss. Gastroenterology. 2010;138(3):896–904.
dc.sourceBrozek W, Reichardt B, Zwerina J, Dimai HP, Klaushofer K ZE. Use of proton pump inhibitors and mortality after hip fracture in a nationwide study. Osteoporos. 2017;28(5):1587–95.
dc.sourceHussain S, Siddiqui AN, Habib A, Hussain MS NA. Proton pump inhibitors’ use and risk of hip fracture: a systematic review and meta-analysis. Rheumatol Int. 2018;38(11):1999–2014.
dc.sourceTargownik LE, Leslie WD, Davison KS, Goltzman D, Jamal SA, Kreiger N, Josse RG, Kaiser SM, Kovacs CS, Prior JC ZWCRG. The relationship between proton pump inhibitor use and longitudinal change in bone mineral density: a population-based study [corrected] from the Canadian Multicentre Osteoporosis Study (CaMos). Am J Gastroenterol. 2012;107(9):1361–9.
dc.sourceFreedberg DE, Haynes K, Denburg MR, Zemel BS, Leonard MB, Abrams JA YY. Use of proton pump inhibitors is associated with fractures in young adults: a population-based study. Osteoporos Int. 2015;26(10):2501–7.
dc.sourceSolomon DH, Diem SJ, Ruppert K, Lian YJ, Liu CC, Wohlfart A, Greendale GA FJ. Bone mineral density changes among women initiating proton pump inhibitors or H2 receptor antagonists: a SWAN cohort study. J Bone Min Res. 2015;30(2):232–9.
dc.sourceKim JJ, Jang EJ, Park J SH. Association between proton pump inhibitor use and risk of fracture: A population-based case-control study. PLoS One. 2020;15(7):023516.
dc.sourceBass AJ, Thorsson V, Shmulevich I, Reynolds SM, Miller M, Bernard B, et al. Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014;513(7517):202–9.
dc.sourcevan der Hoorn MMC, Tett SE, de Vries OJ, Dobson AJ PG. The effect of dose and type of proton pump inhibitor use on risk of fractures and osteoporosis treatment in older Australian women: A prospective cohort study. Bone. 2015;81:675–82.
dc.sourceinstname:Universidad del Rosario
dc.sourcereponame:Repositorio Institucional EdocUR
dc.subjectFármacos inhibidores de la bomba de protones (IBP)
dc.subjectCorrelación exposición prolongada a IBP y osteoporosis
dc.subjectUso de Bifosfonatos o Difosfonatos
dc.subjectUso de Denosumab
dc.subjectUso de Teriparatida
dc.titleAsociación entre la exposición prolongada a inhibidores de la bomba de protones y la prescripción de medicamentos para el abordaje de la osteoporosis en pacientes adultos asegurados al sistema de salud colombiano
dc.typemasterThesis


Este ítem pertenece a la siguiente institución